The urgent Need for Early Preeclampsia Detection

For obstetricians, a primary goal is the early detection, or even prediction, of preeclampsia. This condition, characterized by high blood pressure and elevated protein levels in urine, poses notable risks to both the mother and the developing baby. Preeclampsia is a medical emergency, and early intervention is crucial to mitigate potential complications.

Globally, preeclampsia and other hypertensive disorders of pregnancy are a leading cause of maternal and infant illness and death. According to the World health Organization (WHO), these conditions account for approximately 10-15% of maternal deaths worldwide.

Molecular Signals: Predicting Preeclampsia Months in Advance

Recent research has identified a molecular signal in pregnant women’s blood that can predict the risk of preeclampsia and related conditions months before the onset of symptoms. This discovery offers a significant advancement in prenatal care, potentially allowing for earlier interventions and improved outcomes.

Study Details: Identifying RNA Markers

The study involved a cohort of 10,745 pregnant women over the age of 18, with 9,102 samples included in the final analysis. Blood samples were collected between 17 and 22 weeks of gestation. scientists extracted RNA,a molecule similar to DNA involved in protein production,from the maternal blood. From this, they developed a predictive test.

Promising Results: high Accuracy in High-Risk Pregnancies

The blood test demonstrated a high degree of accuracy, identifying 91% of pregnancies at risk of developing premature preeclampsia in women aged 35 and over without pre-existing high-risk conditions. This prediction was possible several months before any symptoms manifested.

Personalized Pregnancy Care: A Promising Future

Maneesh Jain, co-founder and CEO of Mirvie, the company commercializing the blood test, emphasized the potential for personalized pregnancy care.

Like the discovery of molecular subtypes of breast cancer has led to better results, the discovery of molecular subtypes in [preeclampsia] offer a promising future for the personalization of pregnancy care and the fight against increasing birth rates with complications.
Maneesh Jain, co-founder and CEO of Mirvie

This suggests that identifying specific molecular markers associated with preeclampsia could lead to tailored treatment strategies and improved management of high-risk pregnancies.

Availability and Future Prospects

The clinically validated blood test is expected to be available in the United States under the brand Crossass™ soon. If its performance is consistently confirmed, it might potentially be introduced in Europe subsequently. This new tool represents a significant step forward in the fight against preeclampsia, offering the potential to improve maternal and infant health outcomes worldwide.